Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Vertex Pharmaceuticals
VRTXHealthcareGenerated Jul 5, 2026, 08:52 PM UTC
VRTX (Vertex Pharmaceuticals) analytical snapshot. Return on equity 26.02%, ROA 16.06%, ROIC 27.54%. Net income up ▲ +9.0% YoY. Debt/equity 0.01, current ratio 3.02, net debt -$5.39B. Market cap $134.02B at $528.04 per share. Trailing P/E 38.02, P/S 129.82, P/B 6.92. EV/Operating income ≈ 33.57 (EV $128.63B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -8 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$134.02B
253.81M shares
Price
$528.04
NMS
P/E (ttm)
38.02
Revenue (FY)
—
Net margin
—
Free cash flow
$3.34B
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 20Improving
80% conf
Return on equity 26.02%, ROA 16.06%, ROIC 27.54%. Net income up ▲ +9.0% YoY. Debt/equity 0.01, current ratio 3.02, net debt -$5.39B.
- Return on equity 26.02%, ROA 16.06%, ROIC 27.54%.
- Net income up ▲ +9.0% YoY.
- Debt/equity 0.01, current ratio 3.02, net debt -$5.39B.
Revenue (FY)
—
Net margin
—
ROE
26.02%
ROA 16.06%
ROIC
27.54%
EPS (diluted)
$13.89
FY2025
Free cash flow
$3.34B
Debt / equity
0.01
Cash $5.49B
Current ratio
3.02
Equity $19.36B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $580.4M | — | 0.00 | -119.30 | -127.25 | -$624.3M | -78.57 |
| 2017 | $1.03B | +77.9% | 0.00 | -45.23 | -53.89 | -$410.7M | -48.10 |
| 2018 | — | — | — | — | — | $179.5M | -5.52 |
| 2019 | — | — | — | — | — | $745.5M | — |
| 2020 | — | — | — | — | — | $1.17B | — |
| 2021 | — | — | — | — | — | $1.49B | 26.53 |
| 2022 | — | — | — | — | — | $2.99B | 44.56 |
| 2023 | — | — | — | — | — | $2.41B | 26.96 |
| 2024 | — | — | — | — | — | $3.93B | 32.89 |
| 2025 | — | — | — | — | — | $3.34B | 26.02 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2017 | $714.7M | +79.5% | — | 34.66% |
| Jun 30, 2017 | $1.26B | +51.7% | +76.1% | 21.11% |
| Jun 30, 2017 | $544.1M | -34.4% | -56.8% | 48.84% |
| Sep 30, 2017 | $1.84B | +47.7% | +237.6% | 8.86% |
| Sep 30, 2017 | $578.2M | -53.5% | -68.5% | 28.16% |
| Mar 31, 2018 | $640.8M | -10.3% | +10.8% | 32.81% |
Revenue (annual, SEC 10-K)
2016: 580
2017: 1,032
2018: 0
2019: 0
2020: 0
2021: 0
2022: 0
2023: 0
2024: 0
2025: 0
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: -624
2017: -411
2018: 180
2019: 746
2020: 1,175
2021: 1,494
2022: 2,994
2023: 2,409
2024: 3,925
2025: 3,337
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 25Improving
80% conf
Latest quarterly report (10-Q) filed May 5, 2026. 4 recent 8-K material-event filings in the index. Recent insider Form 4s: 0 buy vs 0 sell transactions.
- Latest quarterly report (10-Q) filed May 5, 2026.
- 4 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Vertex Pharmaceuticals; broad institutional reporting.
- Recent filers include PUZO MICHAEL J, Delaney Dennis R, PUZO MICHAEL J.
- 6 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 14 recent 13G passive institutional ownership notices.
Latest 10-K
—
Latest 10-Q
May 5, 2026
8-K (recent)
4
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
6
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| PUZO MICHAEL J | 13F-HR | Feb 17, 2026 |
| Delaney Dennis R | 13F-HR | Feb 13, 2025 |
| PUZO MICHAEL J | 13F-HR | Nov 10, 2025 |
| Delaney Dennis R | 13F-HR | Feb 17, 2026 |
| PUZO MICHAEL J | 13F-HR | May 7, 2026 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 13, 2026 | 8-K | 8-K |
| May 4, 2026 | 8-K | 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Mar 31, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -76Deteriorating
68% conf
4 risk signal(s), 4 watch item(s) detected from XBRL filing diff analysis. 4 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 18 filing(s).
- NEW: Material weakness in internal controls in latest filing: The term "material weakness" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 22 filing(s).
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 6 filing(s).
- R&D intensity declining: R&D as % of revenue fell from 244.0% to 170.0%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 4 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 7 new risk-language term(s) detected in filing text: Going concern doubt, Material weakness in internal controls, Substantial doubt about ability to continue, Restatement of financial statements, Impairment charge, Restructuring, Off-balance sheet arrangements.
Revenue
$1.03B
+77.9% YoY
Operating income
$3.83B
-11.0% YoY
Net income
$3.62B
+9.0% YoY
Operating cash flow
$3.54B
-14.3% YoY
Capex
$200.4M
-2.1% YoY
Total assets
$22.53B
-0.9% YoY
Total liabilities
$6.12B
+18.9% YoY
Cash & equivalents
$10.50B
+54.6% YoY
Filing quality score
72/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $580.4M | $1.03B | $451.9M | +77.9% |
| Operating income | $4.31B | $3.83B | $-475.4M | -11.0% |
| Net income | $3.32B | $3.62B | $297.6M | +9.0% |
| Operating cash flow | $4.13B | $3.54B | $-592.6M | -14.3% |
| Capex | $204.7M | $200.4M | $-4.3M | -2.1% |
| Total assets | $22.73B | $22.53B | $-197.0M | -0.9% |
| Total liabilities | $5.15B | $6.12B | $973.8M | +18.9% |
| Cash & equivalents | $6.79B | $10.50B | $3.71B | +54.6% |
| Stockholders equity | $10.10B | $13.91B | $3.81B | +37.7% |
| Inventory | $738.8M | $1.21B | $466.6M | +63.2% |
| Accounts receivable | $1.56B | $1.61B | $46.0M | +2.9% |
| R&D expense | $1.42B | $1.75B | $338.0M | +23.9% |
| SG&A expense | $944.7M | $1.14B | $191.9M | +20.3% |
| Interest expense | $69.3M | $72.5M | $3.2M | +4.6% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | InvestmentIncomeNet |
| Removed | AccruedRoyaltiesCurrent, AdvertisingExpense, AmortizationOfIntangibleAssets, BusinessCombinationContingentConsiderationLiabilityNoncurrent, CapitalizedComputerSoftwareAmortization1, CapitalizedComputerSoftwareGross, CashFlowHedgeDerivativeInstrumentAssetsAtFairValue, ContractWithCustomerLiabilityRevenueRecognized, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 18 | 0 | NEW |
| Material weakness in internal controls | high | 22 | 0 | NEW |
| Substantial doubt about ability to continue | high | 3 | 0 | NEW |
| Restatement of financial statements | high | 6 | 0 | NEW |
| Impairment charge | medium | 60 | 0 | NEW |
| Restructuring | medium | 104 | 0 | NEW |
| Off-balance sheet arrangements | medium | 13 | 0 | NEW |
| Related party transactions | low | 34 | 0 | NEW |
Filing signal breakdown
Red flags: 4
Positive: 0
Watch: 4
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $134.02B at $528.04 per share.
- ProPrice & TechnicalsPrice $528.04 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -8
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Vertex Pharmaceuticals is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewReturn on equity **26.02%**, ROA 16.06%, ROIC 27.54%..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow VRTX stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX● you | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |